SciSparc Ltd. (SPRC) Stock Score, Valuation & Financial Research
SciSparc Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 22/100.
Quick answer for SPRC
SciSparc Ltd. currently has a Wall Street Score of 22/100. The stored market price is $5.08. Its financial score is 23/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What SciSparc Ltd. does
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The I
SPRC financial snapshot
- Wall Street Score:
- 22/100
- Current price:
- $5.08
- Market capitalization:
- $294K
- Revenue:
- $2.2M
- Net income:
- $-18.5M
- Free cash flow:
- $-4.1M
- Cash:
- $4.6M
- Total debt:
- $366K
- EPS:
- -259.42
- Financial score:
- 23/100
- Valuation score:
- 0/100
- Revenue score:
- 40/100
What stands out
- Reported year-over-year revenue growth is +1.5%.
- Free cash flow is $-4.1M, showing cash burn in the current stored period.
- The balance sheet shows $4.6M of cash versus $366K of total debt, leaving more cash than debt.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 23/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research SPRC
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.